| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2004 , Vol 46 , Num 2
INFLUENCE OF LANSOPRAZOLE ON HYPOGLYCAEMIC ACTIVITY OF ORAL ANTIDIABETIC AGENTS IN HEALTHY ALBINO RATS
V. L College of Pharmacy, Raichur - Karnataka, India
Viewed :
17432
-
Downloaded :
4656
Drug interaction between sulfonylureas (Tolbutamide and glibenclamide) and lansoprazole (anti-ulcer drug) was studied in healthy albino rats and diabetic rats (alloxan induced diabetes). Hypoglycaemia (onset, Peak effect and duration) induced by tolbutamide (40 mg/kg, po) and glibenclamide (40 µg/kg, po) in rats was observed. Tolbutamide has produced hypoglycaemia to the extent (peak effect) of about 52.60% ± 2.64, onset of action was about 2 hrs and duration was about 34hrs. Similarly the extent of hypoglycaemia induced by glibenclamide was about 52.15% ± 2.07, onset of action was about 2hrs and duration was more than 46 hrs. The same group- of animals was given with lansoprazole 60 mg/kg for one week and then parameters of hypoglycaemia induced by above-mentioned sulfonylureas was observed on the 8th day. Pretreatment with lansoprazole has enhanced the duration of hypoglycaemia induced by tolbutamide i.e 46 hrs, peak effect slightly Le. 57.1 0% ± 1.81 whereas onset of action was not altered significantly. Similarly lansoprazole pretreatment has enhanced the peak effect and duration of hypoglycaemia induced by glibenclamide. In diabetic animals also similar influence of lansoprazole on hypoglycaemia induced by sulfonylureas was observed. Hence, it is suggested that during the concomitant usage of lansoprazole and sulfonylureas, the therapeutic drug monitoring is essential and may also require readjusting the dose and frequency of administration of sulfonylureas.
Keywords :
LANSOPRAZOLE, TOLBUTAMIDE, GLIBENCLAMIDE, HYPOGLYCAEMIC ACTIVITY